TY - JOUR
T1 - Classification, outcomes, and management of misdeployed stents during EUS-guided gastroenterostomy
AU - EUS-GE Study Group
AU - Ghandour, Bachir
AU - Bejjani, Michael
AU - Irani, Shayan S.
AU - Sharaiha, Reem Z.
AU - Kowalski, Thomas E.
AU - Pleskow, Douglas K.
AU - Do-Cong Pham, Khanh
AU - Anderloni, Andrea A.
AU - Martinez-Moreno, Belen
AU - Khara, Harshit S.
AU - D'Souza, Lionel S.
AU - Lajin, Michael
AU - Paranandi, Bharat
AU - Subtil, Jose Carlos
AU - Fabbri, Carlo
AU - Weber, Tobias
AU - Barthet, Marc
AU - Khashab, Mouen A.
AU - Westerveld, Donevan R.
AU - Bashir, Muhammad
AU - Alrajhi, Saad
AU - Aparicio, Jose R.
AU - Confer, Bradley
AU - Huggett, Matthew T.
AU - Peralta-Herce, Sandra
AU - Binda, Cecilia
AU - Messman, Helmut
AU - Sanaei, Omid
AU - Holmes, Ian
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: S. S. Irani: Consultant for Boston Scientific and Gore Medical. R. Z. Sharaiha: Consultant for Boston Scientific, Olympus America, Cook Medical, and Lumendi. T. E. Kowalski: Consultant for Boston Scientific and Medtronic. D. K. Pleskow: Consultant for Boston Scientific, Olympus America, FujiFilm, and Medtronic. K. D.-C. Pham: Consultant for Boston Scientific; speaker for Boston Scientific, Cook Medical, Olympus America, and Taewoong Medical; advisory board of Ambu. A. Anderloni: Consultant for Boston Scientific, Medtronic, and Olympus. H. S. Khara, B. Paranandi, B. Confer: Consultant for Boston Scientific and Merit Endotek. M. Barthet, T. Weber, J. R. Aparicio: Consultant for Boston Scientific. M. A. Khashab: Consultant for Boston Scientific, Apollo, Olympus America, Medtronic, and GI Supply. C. Fiabbri: Consultant for Boston Scientific; speaker for Steris. M. T. Huggett: Consultant for Boston Scientific, Olympus UK, and Cook Medical. All other authors disclosed no financial relationships.
Publisher Copyright:
© 2022 American Society for Gastrointestinal Endoscopy
PY - 2022/1
Y1 - 2022/1
N2 - Background and Aims: Stent misdeployment (SM) has hindered the dissemination of EUS-guided gastroenterostomy (EUS-GE) for gastric outlet obstruction (GOO) management. We aimed to provide a classification system for SM during EUS-GE and study clinical outcomes and management accordingly. Methods: This is a retrospective study involving 16 tertiary care centers (8 in the United States, 8 in Europe) from March 2015 to December 2020. Patients who developed SM during EUS-GE for GOO were included. We propose classifying SM into 4 types. The primary outcome was rate and severity of SM (per American Society for Gastrointestinal Endoscopy lexicon), whereas secondary outcomes were clinical outcomes and management of dislodgement according to the SM classification type, in addition to salvage management of GOO after SM. Results: From 467 EUS-GEs performed for GOO during the study period, SM occurred in 46 patients (9.85%). Most SMs (73.2%) occurred during the first 13 EUS-GE cases by the performing operators. SM was graded as mild (n = 28, 60.9%), moderate (n = 11, 23.9%), severe (n = 6, 13.0%), or fatal (n = 1, 2.2%), with 5 patients (10.9%) requiring surgical intervention. Type I SM was the most common (n = 29, 63.1%), followed by type II (n = 14, 30.4%), type IV (n = 2, 4.3%), and type III (n = 1, 2.2%). Type I SM was more frequently rated as mild compared with type II SM (75.9% vs 42.9%, P =.04) despite an equivalent rate of surgical repair (10.3% vs 7.1%, P =.7). Overall, 4 patients (8.7%) required an intensive care unit stay (median, 2.5 days). The median length of stay was 4 days after SM. Conclusions: Although SM is not infrequent during EUS-GE, most are type I, mild/moderate in severity, and can be managed endoscopically with a surgical intervention rate of approximately 11%.
AB - Background and Aims: Stent misdeployment (SM) has hindered the dissemination of EUS-guided gastroenterostomy (EUS-GE) for gastric outlet obstruction (GOO) management. We aimed to provide a classification system for SM during EUS-GE and study clinical outcomes and management accordingly. Methods: This is a retrospective study involving 16 tertiary care centers (8 in the United States, 8 in Europe) from March 2015 to December 2020. Patients who developed SM during EUS-GE for GOO were included. We propose classifying SM into 4 types. The primary outcome was rate and severity of SM (per American Society for Gastrointestinal Endoscopy lexicon), whereas secondary outcomes were clinical outcomes and management of dislodgement according to the SM classification type, in addition to salvage management of GOO after SM. Results: From 467 EUS-GEs performed for GOO during the study period, SM occurred in 46 patients (9.85%). Most SMs (73.2%) occurred during the first 13 EUS-GE cases by the performing operators. SM was graded as mild (n = 28, 60.9%), moderate (n = 11, 23.9%), severe (n = 6, 13.0%), or fatal (n = 1, 2.2%), with 5 patients (10.9%) requiring surgical intervention. Type I SM was the most common (n = 29, 63.1%), followed by type II (n = 14, 30.4%), type IV (n = 2, 4.3%), and type III (n = 1, 2.2%). Type I SM was more frequently rated as mild compared with type II SM (75.9% vs 42.9%, P =.04) despite an equivalent rate of surgical repair (10.3% vs 7.1%, P =.7). Overall, 4 patients (8.7%) required an intensive care unit stay (median, 2.5 days). The median length of stay was 4 days after SM. Conclusions: Although SM is not infrequent during EUS-GE, most are type I, mild/moderate in severity, and can be managed endoscopically with a surgical intervention rate of approximately 11%.
UR - http://www.scopus.com/inward/record.url?scp=85116557603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116557603&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2021.07.023
DO - 10.1016/j.gie.2021.07.023
M3 - Article
C2 - 34352256
AN - SCOPUS:85116557603
SN - 0016-5107
VL - 95
SP - 80
EP - 89
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 1
ER -